[go: up one dir, main page]

MX342131B - Eliminacion selectiva de celulas erosivas. - Google Patents

Eliminacion selectiva de celulas erosivas.

Info

Publication number
MX342131B
MX342131B MX2013014203A MX2013014203A MX342131B MX 342131 B MX342131 B MX 342131B MX 2013014203 A MX2013014203 A MX 2013014203A MX 2013014203 A MX2013014203 A MX 2013014203A MX 342131 B MX342131 B MX 342131B
Authority
MX
Mexico
Prior art keywords
selective elimination
erosive
cells
treatment
erosive cells
Prior art date
Application number
MX2013014203A
Other languages
English (en)
Other versions
MX2013014203A (es
Inventor
Söderström Kalle
Douglas Galsgaard Elizabeth
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2013014203A publication Critical patent/MX2013014203A/es
Publication of MX342131B publication Critical patent/MX342131B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-NXG2A, o un fragmento de enlace a antígeno del mismo, para usarse en el tratamiento de un paciente que tiene destrucción de cartílago y/o erosión ósea, en donde el anticuerpo anti-NKG2A estimula la eliminación selectiva de células destructivas de cartílago y/o reduce la formación de células que erosinan el hueso.
MX2013014203A 2011-06-17 2012-06-18 Eliminacion selectiva de celulas erosivas. MX342131B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11170402 2011-06-17
US201161501533P 2011-06-27 2011-06-27
PCT/EP2012/061583 WO2012172102A1 (en) 2011-06-17 2012-06-18 Selective elimination of erosive cells

Publications (2)

Publication Number Publication Date
MX2013014203A MX2013014203A (es) 2014-01-20
MX342131B true MX342131B (es) 2016-09-14

Family

ID=44904625

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013014203A MX342131B (es) 2011-06-17 2012-06-18 Eliminacion selectiva de celulas erosivas.

Country Status (11)

Country Link
US (4) US9512228B2 (es)
EP (1) EP2721068B1 (es)
JP (1) JP6334395B2 (es)
KR (1) KR102047248B1 (es)
CN (1) CN103635487B (es)
AU (1) AU2012268939B2 (es)
BR (1) BR112013032217B1 (es)
CA (1) CA2838220C (es)
MX (1) MX342131B (es)
RU (1) RU2617056C2 (es)
WO (1) WO2012172102A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007935A (es) 2004-12-28 2007-12-06 Innate Pharma Sa Anticuerpos monoclonales contra nkg2a.
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
MX342131B (es) * 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
JP2017538660A (ja) * 2014-09-16 2017-12-28 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｎｋｇ２ａ抗体を使用した治療計画
CA2957491A1 (en) * 2014-09-16 2016-03-24 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
RU2721271C2 (ru) 2014-10-23 2020-05-18 Иннейт Фарма Лечение раковых заболеваний с применением анти-nkg2a средств
SG10202000645SA (en) 2016-01-21 2020-03-30 Innate Pharma Neutralization of Inhibitory Pathways in Lymphocytes
KR101926166B1 (ko) * 2016-05-24 2018-12-06 재단법인 아산사회복지재단 수용체 시너지 활성을 이용한 nk 세포의 활성도 검사 방법 및 이를 이용한 nk 세포의 활성도가 관련된 질환의 진단 방법
KR20200133233A (ko) 2018-03-13 2020-11-26 이나뜨 파르마 두부경부암의 치료
US12209126B2 (en) 2018-05-15 2025-01-28 Medimmune Limited Treatment of cancer
EP3946455A4 (en) * 2019-03-29 2022-12-21 Dren Bio, Inc. METHOD OF REDUCING THE CONCENTRATION OF LARGE GRANULAR LYMPHOCYTES AND NATURAL KILLER CELLS
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
MX2023003685A (es) 2020-09-30 2023-06-02 Dren Bio Inc Anticuerpos anti-cd94 y metodos de uso de los mismos.
CN114524876A (zh) * 2020-11-23 2022-05-24 南京北恒生物科技有限公司 靶向nkg2a的抗体及其用途

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
JPH03112485A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｃ遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112487A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd ＨＬＡ―Ｂｗ５３遺伝子およびＤＮＡプローブ並びに形質転換細胞
JPH03112486A (ja) 1989-09-22 1991-05-14 Olympus Optical Co Ltd Ｈｌａ―ｂ３５遺伝子およびｄｎａプローブ並びに形質転換細胞
JPH03112484A (ja) 1989-09-26 1991-05-14 Nisshin Seito Kk 新規制限酵素及びその製造方法
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH03112484U (es) 1990-03-02 1991-11-18
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP0770628B9 (en) 1994-07-13 2007-02-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
EP0981548A4 (en) 1997-04-30 2005-11-23 Enzon Inc GLYCOSYLATABLE SINGLE CHAIN ANTIGEN-BINDING PROTEINS, MANUFACTURE AND USE THEREOF
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
US20040038339A1 (en) 2000-03-24 2004-02-26 Peter Kufer Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US6999941B1 (en) 2000-07-11 2006-02-14 Amazon.Com, Inc. Providing gift clustering functionality to assist a user in ordering multiple items for a recipient
AU2002219229B2 (en) 2000-12-18 2007-12-20 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Means for the diagnosis and therapy of CTCL
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20030095965A1 (en) 2001-05-02 2003-05-22 Katrien Van Beneden Antibodies to Ly49E and CD94/NKG2 receptors
EP1406928B1 (en) 2001-07-19 2010-04-14 Innate Pharma Ntb-a, a surface molecule involved in natural killer cells activity
EP1423140A2 (en) 2001-07-31 2004-06-02 Karl Petter Söderström Compositions and methods for modulation of immune responses
AU2003233894A1 (en) 2002-05-13 2003-11-11 Envirotech Products Limited Tank valve testing method
DE60305919T2 (de) 2002-06-28 2007-01-18 Domantis Limited, Cambridge Dual-specifische liganden mit erhöhter halbwertszeit
RU2326127C2 (ru) 2002-12-16 2008-06-10 Джинентех, Инк. Варианты иммуноглобулинов и их применение
CN1748143A (zh) 2002-12-16 2006-03-15 健泰科生物技术公司 表达人cd20和/或cd16的转基因小鼠
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
JP2008502597A (ja) 2004-04-30 2008-01-31 イネイト・ファーマ Ｎｋ型ｌｄｇｌのような免疫増殖性障害を処置するための組成物および方法
AU2005250499B2 (en) * 2004-06-03 2011-12-08 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
MX2007007935A (es) 2004-12-28 2007-12-06 Innate Pharma Sa Anticuerpos monoclonales contra nkg2a.
CN101107269B (zh) 2004-12-28 2012-10-31 依奈特制药公司 抗nkg2a的单克隆抗体
EP2322557B1 (en) * 2005-10-14 2017-08-30 Innate Pharma Compositions and methods for treating proliferative disorders
NO346945B1 (no) 2006-06-30 2023-03-13 Novo Nordisk As Anti-NKG2A-antistoffer og anvendelser derav
EP2628753A1 (en) 2008-01-24 2013-08-21 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
US20170253658A1 (en) 2014-08-28 2017-09-07 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
CA2957491A1 (en) 2014-09-16 2016-03-24 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
JP2017538660A (ja) 2014-09-16 2017-12-28 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 抗ｎｋｇ２ａ抗体を使用した治療計画
RU2721271C2 (ru) 2014-10-23 2020-05-18 Иннейт Фарма Лечение раковых заболеваний с применением анти-nkg2a средств
SG10202000645SA (en) 2016-01-21 2020-03-30 Innate Pharma Neutralization of Inhibitory Pathways in Lymphocytes

Also Published As

Publication number Publication date
RU2013158625A (ru) 2015-07-27
CA2838220C (en) 2020-07-21
US20170073417A1 (en) 2017-03-16
RU2617056C2 (ru) 2017-04-19
JP2014519522A (ja) 2014-08-14
JP6334395B2 (ja) 2018-05-30
US20200109206A1 (en) 2020-04-09
MX2013014203A (es) 2014-01-20
CA2838220A1 (en) 2012-12-20
US9512228B2 (en) 2016-12-06
WO2012172102A1 (en) 2012-12-20
CN103635487A (zh) 2014-03-12
KR20140037918A (ko) 2014-03-27
BR112013032217A2 (pt) 2016-11-22
US20140161802A1 (en) 2014-06-12
US20230416374A1 (en) 2023-12-28
US11697687B2 (en) 2023-07-11
EP2721068B1 (en) 2018-12-05
EP2721068A1 (en) 2014-04-23
KR102047248B1 (ko) 2019-11-21
AU2012268939B2 (en) 2017-05-04
BR112013032217B1 (pt) 2021-01-19
CN103635487B (zh) 2016-10-12

Similar Documents

Publication Publication Date Title
MX342131B (es) Eliminacion selectiva de celulas erosivas.
UY34387A (es) Composiciones para el tratamiento de la artritis reumatoide y métodos para su utilización.
PH12018501376A1 (en) Processing biomass and energy
MX2013003681A (es) Ácidos nucleicos manipulados y métodos de uso de los mismos.
MX2017007538A (es) Sintesis de ácido nucleíco de volúmen pequeño, alta eficiencia.
MX2019003616A (es) Celulas beta derivadas de celulas madre (sc-beta) y composiciones y metodos para generarlas.
MX2016002571A (es) Regulador de ph de transduccion.
BR112013032229A2 (pt) método de tratamento hidrocatalítico hidrotérmico de biomassa, e, composição
MY160608A (en) APTAMERS TO ß-NGF AND THEIR USE IN TREATING ß-NGF MEDIATED DISEASES AND DISORDERS
MX2018009553A (es) Metodos de seleccion.
MX2014001383A (es) Colageno 7 y metodos relacionados.
PH12013500703A1 (en) Human oncostatin m antibodies and methods of use
NZ717399A (en) Antibodies against csf-1r
GT201200011A (es) Diferenciación de células madre mesenquimales
WO2010107914A3 (en) Biomass production and processing and methods of use thereof
PL3013758T3 (pl) Instalacja do przetwarzania i odzyskiwania odpadów pochodzących od zwierząt hodowlanych obejmująca metanizację, kultury mikroalg i makrofitów oraz wermikulturę
PH12013500500A1 (en) Fused heteroaryls and their uses
CL2011001427A1 (es) Compuestos derivados de 4-azetidinil-1-heteroaril-ciclohexanol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, aterosclerosis, artritis reumatoide, entre otras.
BR112014011254A2 (pt) 2-tiopirimidinonas
FI20115328A0 (fi) Uusia kutinaaseja, niiden tuottaminen ja käytöt
MY155330A (en) Methods for salt production
MX2015003700A (es) Celda para electrolizar un liquido.
MX2016008261A (es) Ras opuesta (rop) y moleculas de acido nucleico relacionadas que confieren resistencia a plagas de coleopteros y hemipteros.
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
GB201101639D0 (en) Biomarkers for osteoarthritis

Legal Events

Date Code Title Description
FG Grant or registration